1 / 16

Title Slide

Title Slide. Clinical Cancer Research using Emerging Advanced Technologies for Health. Breast Cancer Mortality in Women, 1951-2000. Lancet: 365,1727,2005. The CREATE Health team. Clinical Oncology. Proteomics. Genomics. Nano technology. Bioinformatics. Tumour biology. Proteomics.

garrison-meadows
Download Presentation

Title Slide

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Title Slide Clinical Cancer Research using Emerging Advanced Technologies for Health

  2. Breast Cancer Mortality in Women, 1951-2000 Lancet: 365,1727,2005

  3. The CREATE Health team Clinical Oncology Proteomics Genomics Nano technology Bioinformatics Tumour biology Proteomics

  4. Organisation Scientific Secretary CREATE Health Board Representatives from Lund University and Industry Director Carl Borrebaeck Deputy Carsten Rose Financial Officer Steering Committee Scientific Advisory Board IPR Review board Administration Proteomics P James RNA/protein arrays C Borrebaeck Bioinformatics C Peterson DNA/RNA arrays Å Borg Clinical Oncology C Rose Tumor cell biology S Påhlman Nano- technology T Laurell J Häkkinen J Vallon C Rovira F Levander G Marko-Varga J Nilsson C Graffman M Ridderheim H Axelson C Larsson S Ek C Wingren

  5. Localisation of BMC and USil

  6. Localisation at the Biomedical Centre You are here!

  7. Mission and Vision Statements • To create an integrative approach to solve complex • clinical problems, by developing novel techniques - • ”from bedside to bench and back again” • To create a substantial social impact for the patient • through direct application of research for selection • of an optimal, individually-based, cancer treatment

  8. Research and Development • Clinical focus • To associate specific gene and/or protein signatures with: • Treatment-induced drug resistance • Treatment response & optimisation • Tumour relapse & survival time • To identify novel targets for antibody-based therapy

  9. CREATE Health Work flow Clinic CREATE Health Centre Clinic Sample handling Technology development & application Diagnostics/Treatment Data analysis & mining Sample storage & tracking Sample collection Sample analysis Treatment validation Sample processning Clinical transfer Diagnostic validation Technology development Investigators: Carl Borrebaeck Åke Borg Peter James Thomas Laurell Carsten Peterson Sven Påhlman Carsten Rose

  10. Benefits for the patients • Improved diagnosis • Increased analytical sensitivity and capacity • Improved prediction of disease progression • Proteome-wide biomarker identification from fine needle/sure-cut biopsies • Increased survival • Disease stratification and tailoring of therapy • Tumour specific antibodies for therapy

  11. Discovery Projects • Genomics focus • define gene defects that are hereditary • define chromosomal defects arising in cancer • develop pathway focused gene monitoring methods • find novel microRNA markers of cancer • Proteomics focus • discover protein markers of disease in cancer cells • validate markers in serum for subsequent blood tests • develop peptide monitoring for plasma analysis

  12. Practical Application Projects • Antibody microarrays • antibody microarray based oncoproteomics • nanostructured high performance chips for fluorescence/MS • protein sampling in nanoscale for LCM single cell proteome • Proteomic data basis & tools • BASE & Proteios integrated algorithms for breast & lymphomas • Cell reconstruction & validation

  13. Principle of Antibody Microarrays

  14. Practical Example:Pancreatic Adenocarcinomas Healthy Carcinoma • Analysis of serum proteomes from 30 pancreatic • carcinoma patients and • 15 healthy individuals • red- upregulated • black - no change • green- down regulated 100% Sensitivity 100% Specificity

  15. Technology Transfer and Commercialisation CREATE Health is actively engaged in developing its discoveries to benefit society and has a special board for IP issues. The CREATE Health team has generated > three world-wide patents/year over the past five years, ranging from basic research to applied biomedical inventions As a result, six spin-off firms have been created, some with > 100 employees.

  16. End Slide www.createhealth.lth.se

More Related